Lyme Treatment Report

www.LymeTreatmentReport.com

Phase 1

Treating Post-Lyme Disease Syndrome With Acetogenins

https://clinicaltrials.gov/ct2/show/NCT04078841

Treating Post-Lyme Disease Syndrome With Acetogenins

Detailed Description:
To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS). After failure of antibiotic therapy to relive persistent symptoms of Lyme Disease, the use of Acetogenins to elevate Post-Lyme Disease Syndrome.

Study Design
Go to sections
Study Type : Interventional
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Using ReaLife+ to Treat Post-Lyme Disease Syndrome
Actual Study Start Date : July 1, 2019
Actual Primary Completion Date : November 14, 2019
Estimated Study Completion Date : January 30, 2020

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

https://clinicaltrials.gov/ct2/show/NCT03891667

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients will be randomly assigned to one of two groups:

Treatment Group I- patients will receive Disulfiram for 8 weeks

Treatment Group 2 – patients will receive Disulfiram for 4 weeks followed by 4 weeks of placebo.

The dosing starts at 250 mg on day 1, none on day 2, 250 mg on day 3, none on day 4, and then 250 mg x 3 days. If tolerated, the dose is then increased to 500 mg/day.

Primary outcome is at week 10. Patients will be reassessed at week 14.

Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: This is a placebo-controlled study using matching capsules for disulfiram and placebo. Neither the participant, the care provider, nor the investigator will know the randomized assignment. The research pharmacy and a researcher not involved with this study will keep the code regarding group assignment.
Primary Purpose: Treatment
Official Title: Disulfiram (“Antabuse”): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Actual Study Start Date : July 31, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis [Completed]

https://clinicaltrials.gov/ct2/show/NCT03010228

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 179 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Actual Study Start Date : January 2017
Actual Primary Completion Date : September 28, 2017
Actual Study Completion Date : January 16, 2019

Back to top